‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework
Open Access
- 25 June 2019
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 75 (9) , 1181-1192
Abstract
Background Engagement of patients and healthcare professionals is increasingly considered as fundamental to pharmacovigilance and risk minimisation activities. Few empirical studies of engagement exist and a lack of explicit conceptualisations impedes effective measurement, research and the development of evidence-based engagement interventions. Aims This article (1) develops a widely applicable conceptualisation, (2) considers various methodological challenges to researching engagement, proposing some solutions, and (3) outlines a basis for converting the conceptualisation into specific measures and indicators of engagement among stakeholders. Method We synthesise social science work on risk governance and public understandings of science with insights from studies in the pharmacovigilance field. Findings This leads us to define engagement as an ongoing process of knowledge exchange among stakeholders, with the adoption of this knowledge as the outcome which may feed back into engagement processes over time. We conceptualise this process via three dimensions; breadth, depth and texture. In addressing challenges to capturing each dimension, we emphasise the importance of combining survey approaches with qualitative studies and secondary data on medicines use, prescribing, adverse reaction reporting and health outcomes. A framework for evaluating engagement intervention processes and outcomes is proposed. Alongside measuring engagement via breadth and depth, we highlight the need to research the engagement process through attentiveness to texture—what engagement feels like, what it means to people, and how this shapes motivations based on values, emotions, trust and rationales. Conclusion Capturing all three dimensions of engagement is vital to develop valid understandings of what works and why, thus informing engagement interventions of patients and healthcare professionals to given regulatory pharmacovigilance scenarios.Keywords
Funding Information
- Universiteit van Amsterdam
This publication has 68 references indexed in Scilit:
- The future of safety science is happening now: The modernization of the benefit‐risk paradigmPharmacoepidemiology and Drug Safety, 2017
- Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistPharmacoepidemiology and Drug Safety, 2015
- Factors influencing quality decision‐making: regulatory and pharmaceutical industry perspectivesPharmacoepidemiology and Drug Safety, 2015
- Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best PracticesDrug Safety, 2014
- Systematic Collection of Patient-Reported Adverse Drug Reactions: A Path to Patient-Centred PharmacovigilanceDrug Safety, 2013
- Coping with Complexity, Uncertainty and Ambiguity in Risk Governance: A SynthesisAMBIO, 2011
- The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case–control studyPharmacoepidemiology and Drug Safety, 2010
- Motives for reporting adverse drug reactions by patient-reporters in the NetherlandsEuropean Journal of Clinical Pharmacology, 2010
- Public Deliberation and Governance: Engaging with Science and Technology in Contemporary EuropeMinerva, 2006
- Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid programPharmacoepidemiology and Drug Safety, 2004